Cancer

SS Innovations International Sells First SSi Mantra in the Middle East

The first international sale of the SSi Mantra was delivered to Dubai, United Arab Emirates Additional International Sales Expected FORT…

1 year ago

AlzeCure Publishes the Positive Clinical Results from the Phase I Trial of NeuroRestore ACD856 Against Alzheimer’s

STOCKHOLM, SWEDEN / ACCESSWIRE / August 9, 2023 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a…

1 year ago

Science & Humans (S&H) Welcomes Esteemed Canadian Endocrinologist & Geneticist Dr. Fady Hannah-Shmouni to Medical Advisory Board

MISSISSAUGA, ON / ACCESSWIRE / August 8, 2023 / Science & Humans (S&H), a health and wellness company focused on…

1 year ago

Establishment Labs Reports Record Second Quarter 2023 Financial Results

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness,…

1 year ago

NervGen Pharma to Proceed with Landmark Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury Having Completed FDA Review and Received IRB Approval

Recruitment of individuals with spinal cord injury (SCI) initiated at Shirley Ryan AbilityLab in ChicagoChronic SCI cohort results expected in…

1 year ago

NeoGenomics Reports Second Quarter 2023 Results

Second Quarter Revenue Increased 18% to $147 MillionFORT MYERS, FL / ACCESSWIRE / August 8, 2023 / NeoGenomics, Inc. (NASDAQ:NEO)…

1 year ago

Precipio Launches Its Much-Anticipated Quantitative BCR-ABL 2.0 Panel

Advanced panel already generating six-figure pre-ordersNEW HAVEN, Conn., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc.…

1 year ago

Viracta Therapeutics Announces Publication in Blood Advances Demonstrating Promising and Durable Signal of Nana-val Efficacy in Patients with Relapsed or Refractory (R/R) Epstein-Barr Virus-Positive (EBV+) Lymphoma

Results from Phase 1b/2 trial showed complete responses achieved and ongoing durable responses observed out to approximately 36 months across…

1 year ago

Sensus Healthcare Announces New $3 Million Share Repurchase Program

BOCA RATON, Fla., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in…

1 year ago